PEOPLECHART CORPORATION – Trademark Portfolio
Entity Type: 03
PEOPLECHART CORPORATION holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include INCONTEXT and PEOPLECHART INFORMATION YOU CAN LIVE WITH. The owner is based in SAN FRANCISCO, CA.
220 SANSOME STREET
SUITE 980
SAN FRANCISCO, CA 94014
Showing of trademarks Trademarks
Trademark Classifications
PEOPLECHART CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does PEOPLECHART CORPORATION have?
PEOPLECHART CORPORATION has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does PEOPLECHART CORPORATION file in?
PEOPLECHART CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 39 (Transportation & Storage). Class 42 covers scientific and technological services; industrial analysis and research services.
What are PEOPLECHART CORPORATION's most well-known trademarks?
PEOPLECHART CORPORATION's registered trademark portfolio includes well-known marks such as INCONTEXT and PEOPLECHART INFORMATION YOU CAN LIVE WITH. These are among 2 currently registered trademarks in the portfolio.
What is PEOPLECHART CORPORATION's trademark registration success rate?
PEOPLECHART CORPORATION has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.